Publication: Neuropathic MORC2 mutations perturb GHKL ATPase dimerization dynamics and epigenetic silencing by multiple structural mechanisms
Open/View Files
Date
2018
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Nature Publishing Group UK
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Douse, Christopher H., Stuart Bloor, Yangci Liu, Maria Shamin, Iva A. Tchasovnikarova, Richard T. Timms, Paul J. Lehner, and Yorgo Modis. 2018. “Neuropathic MORC2 mutations perturb GHKL ATPase dimerization dynamics and epigenetic silencing by multiple structural mechanisms.” Nature Communications 9 (1): 651. doi:10.1038/s41467-018-03045-x. http://dx.doi.org/10.1038/s41467-018-03045-x.
Research Data
Abstract
Missense mutations in MORC2 cause neuropathies including spinal muscular atrophy and Charcot–Marie–Tooth disease. We recently identified MORC2 as an effector of epigenetic silencing by the human silencing hub (HUSH). Here we report the biochemical and cellular activities of MORC2 variants, alongside crystal structures of wild-type and neuropathic forms of a human MORC2 fragment comprising the GHKL-type ATPase module and CW-type zinc finger. This fragment dimerizes upon binding ATP and contains a hinged, functionally critical coiled-coil insertion absent in other GHKL ATPases. We find that dimerization and DNA binding of the MORC2 ATPase module transduce HUSH-dependent silencing. Disease mutations change the dynamics of dimerization by distinct structural mechanisms: destabilizing the ATPase-CW module, trapping the ATP lid, or perturbing the dimer interface. These defects lead to the modulation of HUSH function, thus providing a molecular basis for understanding MORC2-associated neuropathies.
Description
Other Available Sources
Keywords
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service